National Securities Initiates Coverage on Dyax (DYAX) with a Buy
DYAX Hot Sheet
Rating Summary:0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 1
National Securities initiates coverage on Dyax (Nasdaq: DYAX) with a Buy. Price target $5.
To see more analyst ratings on DYAX Click Here.
Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications.
To see more analyst ratings on DYAX Click Here.
Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications.
You May Also Be Interested In
- UPDATE: Canaccord Genuity Starts KIT Digital (KITD) at Hold; OTT Video Trends Remain Strong, But Concerns Remain
- Stifel Nicolaus Starts Trustmark (TRMK) at Hold
- Imperial Capital Starts Scorpio Tankers (STNG) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
